Research programme: nucleoside inhibitors - Gilead SciencesAlternative Names: 4'-substituted 2'd2'F nucleoside analogues - Gilead; 4'-substituted β-d-2'-deoxy-2'-α-fluoro nucleoside inhibitors - Gilead
Latest Information Update: 17 Jun 2015
At a glance
- Originator Gilead Sciences
- Class Antivirals
- Mechanism of Action Polymerase inhibitors; Viral RNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 29 Apr 2015 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route)